doi: 10.1016/j.vaccine.2009.08.045.
Epub 2009 Aug 29.
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States
Affiliations
- PMID: 19720366
- DOI: 10.1016/j.vaccine.2009.08.045
Item in Clipboard
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States
Vaccine.
.
Abstract
Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000-2006, incorporating direct and indirect effects on incidence of invasive pneumococcal disease (IPD), hospitalized pneumonia and otitis media. Before accounting for indirect effects, PCV7 cost $201,000 per life-year saved. After incorporating indirect effects on IPD, cost per life-year saved was $10,400. The presence of modest additional indirect effects against hospitalized pneumonia and otitis media in children may have resulted in overall cost savings.
Similar articles
-
The cost-effectiveness of pneumococcal conjugate vaccination in Australia.Vaccine. 2004 Mar 12;22(9-10):1138-49. doi: 10.1016/j.vaccine.2003.09.036. Vaccine. 2004. PMID: 15003641
-
Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8. MMWR Morb Mortal Wkly Rep. 2008. PMID: 18272956
-
Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.Pediatr Infect Dis J. 2006 Jun;25(6):494-501. doi: 10.1097/01.inf.0000222403.42974.8b. Pediatr Infect Dis J. 2006. PMID: 16732146
-
The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Clin Ther. 2008. PMID: 18343273 Review.
-
Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.Expert Rev Vaccines. 2008 Feb;7(1):83-95. doi: 10.1586/14760584.7.1.83. Expert Rev Vaccines. 2008. PMID: 18251696 Review.
Cited by
-
Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Pharmacoeconomics. 2011. PMID: 21250759 Review.
-
The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis.PLoS One. 2021 Apr 8;16(4):e0249497. doi: 10.1371/journal.pone.0249497. eCollection 2021. PLoS One. 2021. PMID: 33831049 Free PMC article.
-
Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis.Infect Immun. 2011 Jan;79(1):288-97. doi: 10.1128/IAI.00631-10. Epub 2010 Nov 1. Infect Immun. 2011. PMID: 21041497 Free PMC article.
-
Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.BMJ Glob Health. 2018 May 9;3(3):e000636. doi: 10.1136/bmjgh-2017-000636. eCollection 2018. BMJ Glob Health. 2018. PMID: 29765775 Free PMC article.
-
Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.Hum Vaccin Immunother. 2016 May 3;12(5):1202-16. doi: 10.1080/21645515.2015.1131369. Epub 2016 Feb 2. Hum Vaccin Immunother. 2016. PMID: 26837602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
